Investment firm Wall Street Zen has downgraded Vaxcyte’s stock from ‘sell’ to ‘strong sell’ due to concerns about the company’s recent developments, despite other analysts maintaining a ‘Moderate Buy’ consensus. Vaxcyte is focused on developing a new 24-valent pneumococcal vaccine, VAX-24, and will face scrutiny as investors watch for updates on its progress and regulatory milestones. The mixed sentiment surrounding Vaxcyte reflects broader challenges in the biotech and vaccine development sectors.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://nationaltoday.com/us/ca/san-carlos/news/2026/04/12/wall-street-zen-downgrades-vaxcyte-stock-to-strong-sell/
